戈谢氏病致病机制及治疗方法

doi:10.16288/j.yczz.14-459

遗传 ›› 2015, Vol. 37 ›› Issue (6): 510-516.doi: 10.16288/j.yczz.14-459

戈谢氏病致病机制及治疗方法

刘林玉¹, 杜司晨², 张进¹, 马端^{1, 2}

1.复旦大学代谢与分子医学教育部重点实验室,上海 200032;
2.复旦大学出生缺陷研究中心,上海 200032

收稿日期:2014-12-25 修回日期:2015-01-23 出版日期:2015-06-20 发布日期:2015-03-18
通讯作者: 马端,博士, 教授,研究方向：出生缺陷与血管性疾病的发病机制与干预策略。E-mail: duanma@fudan.edu.cn
作者简介:刘林玉,硕士研究生,专业方向：生物化学与分子生物学。E-mail: llynvxia@126.com 杜司晨,博士研究生,专业方向：医学系统生物学。E-mail: xiaodu1224@sina.com刘林玉和杜司晨并列第一作者。
基金资助:
国家自然科学基金项目(编号：81371269)和上海市科研计划项目(编号：14140902600)资助

Pathogenic mechanism and therapies for Gaucher’s disease

Linyu Liu¹, Sichen Du², Jin Zhang¹, Duan Ma^{1, 2}

1. The Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, Shanghai 200032, China;
2. Research Center for Birth Defects, Fudan University, Shanghai 200032, China

Received:2014-12-25 Revised:2015-01-23 Online:2015-06-20 Published:2015-03-18

摘要/Abstract

摘要： 戈谢氏病(Gaucher's disease,GD)又称葡萄糖脑苷脂沉积病,是溶酶体贮积症(Lysosomal storage disorder)中最常见的一种,为常染色体隐性遗传病。此病因溶酶体中β-葡糖脑苷脂酶(β-glucocerebrosidase, GBA)编码基因异常,致使该酶活性降低,葡糖脑苷脂(Glucocerebroside, GlcCer)不能被水解而聚积在脑组织、肝脏、脾等组织的溶酶体及单核–巨噬系统中,导致细胞失去原有的功能而产生一系列症状：脑损伤、肝脾肿大、骨损害、血细胞减少、生长发育迟滞等。Ⅰ型GD以酶替代治疗(Enzyme replacement therapy, ERT)为主,但Ⅱ型和Ⅲ型无有效的治疗方法。文章对GD的致病机制及治疗方法的最新进展进行了综述。

关键词: 戈谢氏病, β, -葡萄糖脑苷脂酶, 致病机制, 酶替代治疗, 基因治疗

Abstract: Gaucher's disease (GD) also named glucocerebroside lipidosis, is the most common kind of 1ysosomal storage disorder. It results from an autosomal recessive deficiency of the lysosomal enzyme acid β-glucosidase/ β-glucocerebrosidase (GBA), which is responsible for hydrolysis of glucocerebroside/glucosylceramide (GlcCer) into glucose and ceramide. Absent or reduced enzymatic activity of GBA leads to multisystemic accumulation of GlcCer in mononuclear phagocyte system and various tissues, such as brain, liver, spleen and so on, causing brain injury, liver splenomegaly, bone damage, the reduction of blood cells and individual growth retardation. GD type I could be treated by enzyme replacement therapy (ERT), but GD types II and III have not effective treatment. In this review, we summarize the recent progress on pathogenic mechanism and therapies in GD.

Key words: Gaucher's disease, β, -glucocerebrosidase, pathogenic mechanism, enzyme replacement therapy, gene therapy

刘林玉, 杜司晨, 张进, 马端. 戈谢氏病致病机制及治疗方法[J]. 遗传, 2015, 37(6): 510-516.

Linyu Liu, Sichen Du, Jin Zhang, Duan Ma. Pathogenic mechanism and therapies for Gaucher’s disease[J]. HEREDITAS(Beijing), 2015, 37(6): 510-516.

参考文献

[1] van Dussen L, Biegstraaten M, Hollak CE, Dijkgraaf MG. Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease. Orphanet J Rare Dis , 2014, 9(1): 51-63.
[2] Sobreira E, Pires RF, Cizmarik M, Grabowski GA. Phenotypic and genotypic heterogeneity in Gaucher disease type 1: a comparison between Brazil and the rest-of-the-world. Mol Genet Metab , 2007, 90(1): 81-86.
[3] Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA , 1999, 281(3): 249-254.
[4] Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet , 2008, 372(9645): 1263-1271.
[5] Chan A, Holleran WM, Ferguson T, Crumrine D, Goker-Alpan O, Schiffmann R, Tayebi N, Ginns EI, Elias PM, Sidransky E. Skin ultrastructural findings in type 2 Gaucher disease: diagnostic implications. Mol Genet Metab , 2011, 104(4): 631-636.
[6] Elstein D, Abrahamov A, Altarescu G, Zimran A. Evolving features in type 3 Gaucher disease on long-term enzyme replacement therapy. Blood Cells Mol Dis , 2013, 50(2): 140.
[7] Bendikov-Bar I, Ron I, Filocamo M, Horowitz M. Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant. Blood Cells Mol Dis , 2011, 46(1): 4-10.
[8] Bendikov-Bar I, Horowitz M. Gaucher disease paradigm: from ERAD to comorbidity. Hum Mutat , 2012, 33(10): 1398-1407.
[9] Yang CZ, Rahimpour S, Lu J, Pacak K, Ikejiri B, Brady RO, Zhuang ZP. Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. Proc Natl Acad Sci USA , 2013, 110(3): 966-971.
[10] Wang F, Chou A, Segatori L. Lacidipine remodels protein folding and Ca 2+ homeostasis in Gaucher's disease fibroblasts: a mechanism to rescue mutant glucocerebrosidase. Chem Biol , 2011, 18(6): 766-776.
[11] Tan YL, Genereux JC, Pankow S, Aerts JMFG, Yates JRIII, Kelly JW. ERdj3 Is an endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to gaucher's disease. Chem Biol , 2014, 21(8): 967-976.
[12] Tamargo RJ, Velayati A, Goldin E, Sidransky E. The role of saposin C in Gaucher disease. Mol Genet Metab , 2012, 106(3): 257-263.
[13] Velayati A, DePaolo J, Gupta N, Choi JH, Moaven N, Westbroek W, Goker-Alpan O, Goldin E, Stubblefield BK, Kolodny E, Tayebi N, Sidransky E. A mutation in SCARB2 is a modifier in Gaucher disease. Hum Mutat , 2011, 32(11): 1232-1238.
[14] Alfonso P, Pampin S, García-Rodríguez B, Tejedor T, Domínguez C, Rodríguez-Rey JC, Giraldo P, Pocoví M. Characterization of the c. (-203)A>G variant in the glucocerebrosidase gene and its association with phenotype in Gaucher disease. Clin Chim Acta , 2011, 412(3-4): 365-369.
[15] Sardi SP, Singh P, Cheng SH, Shihabuddin LS, Schlossmacher MG. Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models. Neurodegener Dis , 2012, 10(1-4): 195-202.
[16] Yap TL, Velayati A, Sidransky E, Lee JC. Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Mol Genet Metab , 2013, 108(1): 56-64.
[17] Grabowski GA. Gaucher disease and other storage disorders. Hematology Am Soc Hematol Educ Program , 2012, 2012(1): 13-18.
[18] Franco M, Collec E, Connes P, van den Akker E, de Villemeur T B, Belmatoug N, von Lindern M, Ameziane N, Hermine O, Colin Y, Le Van Kim C, Mignot C. Abnormal properties of red blood cells suggest a role in the pathophysiology of Gaucher disease. Blood , 2013, 121(3): 546-555.
[19] Liu J, Halene S, Yang M, Iqbal J, Yang RH, Mehal WZ, Chuang WL, Jain D, Yuen T, Sun L, Zaidi M, Mistry PK. Gaucher disease gene GBA functions in immune regulation. Proc Natl Acad Sci USA , 2012, 109(25): 10018-10023.
[20] Mistry PK, Liu J, Yang M, Nottoli T, McGrath J, Jain D, Zhang K, Keutzer J, Chuang WL, Mehal WZ, Zhao HY, Lin AP, Mane S, Liu X, Peng YZ, Li JH, Agrawal M, Zhu LL, Blair HC, Robinson LJ, Iqbal J, Sun L, Zaidi M. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci USA , 2010, 107(45): 19473-19478.
[21] Vitner EB, Farfel-Becker T, Eilam R, Biton I, Futerman AH. Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease. Brain , 2012, 135(Pt 6): 1724-1735.
[22] Degterev A, Huang ZH, Boyce M, Li YQ, Jagtap P, Mizushima N, Cuny GD, Mitchison TJ, Moskowitz MA, Yuan JY. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol , 2005, 1(2): 112-119.
[23] Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol , 2010, 11(10): 700-714.
[24] Vitner EB, Salomon R, Farfel-Becker T, Meshcheriakova A, Ali M, Klein AD, Platt FM, Cox TM, Futerman AH. RIPK3 as a potential therapeutic target for Gaucher's disease. Nat Med , 2014, 20(2): 204-208.
[25] Giraldo P, Irún P, Alfonso P, Dalmau J, Fernández-Galán MA, Figueredo A, Hernández-Rivas JM, Julia A, Luño E, Marín-Jimenez F, Martín-Nuñez G, Montserrat JL, de la Serna J, Vidaller A, Villalón L, Pocovi M. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage. Blood Cells Mol Dis , 2011, 46(1): 115-118.
[26] Khalifa AS, Tantawy AA, Shawky RM, Monir E, Elsayed SM, Fateen E, Cooper A. Outcome of enzyme replacement therapy in children with Gaucher disease: The Egyptian experience. Egypt J Med Human Genet , 2011, 12(1): 9-14.
[27] Elstein D, Haims AH, Zahrieh D, Cohn GM, Zimran A. Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up. Blood Cells Mol Dis , 2014, 53(1-2): 56-60.
[28] van Dussen L, Zimran A, Akkerman EM, Aerts JMFG, Petakov M, Elstein D, Rosenbaum H, Aviezer D, Brill- Almon E, Chertkoff R, Maas M, Hollak CE. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood Cells Mol Dis , 2013, 50(3): 206-211.
[29] Lee JY, Lee BH, Kim GH, Jung CW, Lee J, Choi JH, Yoo HW. Clinical and genetic characteristics of Gaucher disease according to phenotypic subgroups. Korean J Pediatr , 2012, 55(2): 48-53.
[30] Singla M, Arivarasan K, Dhir V, Sharma P, Sharma A, Sharma S, Singh S. Medical image. an unusual cause of massive splenomegaly in an adult. Gaucher's disease. N Z Med J , 2012, 125(1361): 98-101.
[31] Suzuki Y. Chaperone therapy update: Fabry disease, G M1 -gangliosidosis and Gaucher disease. Brain Dev , 2013, 35(6): 515-523.
[32] Kamath RS, Lukina E, Watman N, Dragosky M, Pastores GM, Arreguin EA, Rosenbaum H, Zimran A, Aguzzi R, Puga AC, Norfleet AM, Peterschmitt MJ, Rosenthal DI. Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat. Skeletal Radiol , 2014, 43(10): 1353-1360.
[33] Ayto RM, Hughes DA, Jeevaratnam P, Rolles K, Burroughs AK, Mistry PK, Mehta AB, Pastores GM. Long- term outcomes of liver transplantation in type 1 Gaucher disease. Am J Transplant , 2010, 10(8): 1934-1939.
[34] Khanna R, Soska R, Lun Y, Feng J, Frascella M, Young B, Brignol N, Pellegrino L, Sitaraman SA, Desnick RJ, Benjamin ER, Lockhart DJ, Valenzano KJ. The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. Mol Ther , 2010, 18(1): 23-33.
[35] Xiao JB, Westbroek W, Motabar O, Lea WA, Hu X, Velayati A, Zheng W, Southall N, Gustafson AM, Goldin E, Sidransky E, Liu K, Simeonov A, Tamargo RJ, Ribes A, Matalonga L, Ferrer M, Marugan JJ. Discovery of a novel noniminosugar acid α glucosidase chaperone series. J Med Chem , 2012, 55(17): 7546-7559.
[36] Wang GN, Twigg G, Butters TD, Zhang SW, Zhang LR, Zhang LH, Ye XS. Synthesis of N -substituted ε-hexonolactams as pharmacological chaperones for the treatment of N370S mutant Gaucher disease. Org Biomol Chem , 2012, 10(15): 2923-2927.
[37] Schönemann W, Gallienne E, Ikeda-Obatake K, Asano N, Nakagawa S, Kato A, Adachi I, Górecki M, Frelek J, Martin OR. Glucosylceramide mimics: highly potent GCase inhibitors and selective pharmacological chaperones for mutations associated with types 1 and 2 Gaucher disease. Chem Med Chem , 2013, 8(11): 1805-1817.
[38] Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, Baldoli C, Martino S, Calabria A, Canale S, Benedicenti F, Vallanti G, Biasco L, Leo S, Kabbara N, Zanetti G, Rizzo WB, Mehta NAL, Cicalese MP, Casiraghi M, Boelens JJ, Del Carro U, Dow DJ, Schmidt M, Assanelli A, Neduva V, Di Serio C, Stupka E, Gardner J, von Kalle C, Bordignon C, Ciceri F, Rovelli A, Roncarolo MG, Aiuti A, Sessa M, Naldini L. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science , 2013, 341(6148): 1233158.
[39] Mahuran DJ, Clarke JTR, Callahan JW. Products and Methods for Gaucher Disease Therpy, 2004.
[40] McEachern KA, Nietupski JB, Chuang WL, Armentano D, Johnson J, Hutto E, Grabowski GA, Cheng SH, Marshall J. AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease. J Gene Med , 2006, 8(6): 719-729.
[41] Selden NR, Al-Uzri A, Huhn SL, Koch TK, Sikora DM, Nguyen-Driver MD, Guillaume DJ, Koh JL, Gultekin SH, Anderson JC, Vogel H, Sutcliffe TL, Jacobs Y, Steiner RD. Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis. J Neurosurg Pediatr , 2013, 11(6): 643-652.
[42] Enquist IB, Nilsson E, Ooka A, Månsson JE, Olsson K, Ehinger M, Brady RO, Richter J, Karlsson S. Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci USA , 2006, 103(37): 13819-13824.
[43] Tiscornia G, Vivas EL, Matalonga L, Berniakovich I, Barragán Monasterio M, Eguizábal C, Gort L, González F, Ortiz Mellet C, García Fernández JM, Ribes A, Veiga A, Izpisua Belmonte JC. Neuronopathic Gaucher's disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds. Hum Mol Genet , 2013, 22(4): 633-645.

编辑推荐

Metrics

www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:

戈谢氏病致病机制及治疗方法

Pathogenic mechanism and therapies for Gaucher’s disease

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	牛煦然,尹树明,陈曦,邵婷婷,李大力. 基因编辑技术及其在疾病治疗中的研究进展[J]. 遗传, 2019, 41(7): 582-598.
[2]	任云晓, 肖茹丹, 娄晓敏, 方向东. 基因编辑技术及其在基因治疗中的应用[J]. 遗传, 2019, 41(1): 18-27.
[3]	陈一欧, 宝颖, 马华峥, 伊宗裔, 周卓, 魏文胜. 基因编辑技术及其在中国的研究发展[J]. 遗传, 2018, 40(10): 900-915.
[4]	李爽,杨圆圆,邱艳,陈彦好,徐璐薇,丁秋蓉. 基因组编辑技术在精准医学中的应用[J]. 遗传, 2017, 39(3): 177-188.
[5]	沈丹,陈才,王赛赛,陈伟,高波,宋成义. Tc1/Mariner转座子超家族的研究进展[J]. 遗传, 2017, 39(1): 1-13.
[6]	刘静茹, 孟莎莎, 周卫辉. 儿童孤独症相关基因NRXN1β启动子功能分析[J]. 遗传, 2015, 37(8): 801-810.
[7]	许烨, 张嘉莹, 杨博宇, 何志宏, 张慕晨, 于珍, 顾鸣敏. 腓骨肌萎缩症4型遗传学研究进展[J]. 遗传, 2015, 37(6): 501-509.
[8]	马晴雯. fC31整合酶系统介导的位点特异性整合研究进展[J]. 遗传, 2011, 33(6): 567-575.
[9]	李林川，韩方普. 人工染色体研究进展[J]. 遗传, 2011, 33(4): 293-297.
[10]	左国伟，吕凤林. 人类人工染色体作为转基因载体的应用前景[J]. 遗传, 2005, 27(6): 995-1000.
[11]	汪宗桂，郑文岭，崔东，马文丽. 哺乳动物中基因持续表达的策略[J]. 遗传, 2004, 26(5): 745-748.
[12]	邱瑞镰. 中国遗传学会会讯[J]. 遗传, 2003, 4(5): 577-580.
[13]	曹月青，周玲，韩柱，尚磊雄，虎良菊，姚文彬. 人胰岛素基因在体内外表达的研究[J]. 遗传, 2002, 24(4): 407-165.
[14]	王柏秋，闫承慧，吴焱，黄承滨，傅松滨，李璞. 高低转移肺腺癌细胞系Anip973和AGZY83-a中P21过表达的研究[J]. 遗传, 2000, 22(5): 277-280.
[15]	汤富酬，韩嵘，薛友纺. RNA/DNA嵌合分子介导的高效基因修复[J]. 遗传, 2000, 22(4): 265-268.